Jing-jing Li

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.

Journal: Frontiers in immunology

Published: March 22, 2022

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.

Journal: Journal of cancer research and clinical oncology

Published: May 12, 2021

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study.

Journal: Frontiers in oncology

Published: July 13, 2020

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.

Journal: Aging

Published: November 17, 2019

Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.

Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.

Journal: Frontiers in oncology

Published: May 12, 2019

A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.

A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.

Journal: Melanoma research

Published: June 03, 2017

Late-stage inhibition of autophagy enhances calreticulin surface exposure.

Late-stage inhibition of autophagy enhances calreticulin surface exposure.

Journal: Oncotarget

Published: September 01, 2015

Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.

Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.

Journal: Medical oncology (Northwood, London, England)

Published: August 06, 2015

Showing 1-8 of 8

Last Updated: 09/26/2026